Kopp, Katherine O.Greer, Margaret E.Glotfelty, Elliot J.Hsueh, Shih-ChangTweedie, DavidKim, Dong SeokReale, MarcellaVargesson, NeilGreig, Nigel H2023-04-272023-04-272023-04-26Kopp, K O, Greer, M E, Glotfelty, E J, Hsueh, S-C, Tweedie, D, Kim, D S, Reale, M, Vargesson, N & Greig, N H 2023, 'A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders', Biomolecules, vol. 13, no. 5, 747. https://doi.org/10.3390/biom130507472218-273XORCID: /0000-0001-8027-114X/work/145270776https://hdl.handle.net/2164/20579Acknowledgements The authors acknowledge support from their associated institutions which included: (i) the Intramural Research Program, National Institute on Aging, NIH, USA, (ii) the Karolinska Institutet, Sweden, (iii) Aevisbio Inc., USA, (iv) Aevis Bio Inc., Republic of Korea, (v) G. d’Annunzio University of Chieti and Pescara, Italy, and (vi) University of Aberdeen, Scotland, UK. Funding The generation of this article was supported by: (i) the Intramural Research Program, National Institute on Aging, NIH: AG000994. (ii) The Technology Development Program of MSS, Republic of Korea (S2782046). (iii) The National Research Foundation (NRF) grant funded by the Republic of Korea Government (2021M3A9G2015889).346954606engSDG 3 - Good Health and Well-beingImmunomodulatory imide drugs (IMiDs)thalidomidepomalidomideneuroinflammationcereblontraumatic brain injury;Alzheimer’s diseaseParkinson’s diseaseneurodegenerationerythema nodosum leprosumR MedicineRJournal article10.3390/biom13050747